IL9抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: HL-60 cell lysate, Primary antibody: P06449(IL9 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P06449(IL9 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Interleukin-9 (IL-9) is a pleiotropic cytokine primarily produced by Th2 cells, mast cells, and innate lymphoid cells. It plays a key role in allergic inflammation, autoimmune diseases, and tumor immunity by promoting mast cell activation, eosinophil recruitment, and mucus production. IL-9 exerts effects through binding to its receptor (IL-9R), a heterodimer of IL-9Rα and γc chains, triggering JAK/STAT signaling pathways. Dysregulated IL-9 signaling is implicated in asthma, atopic dermatitis, and certain cancers.

IL-9-targeting antibodies are therapeutic agents designed to neutralize IL-9 or block its interaction with IL-9R. Monoclonal antibodies (e.g., MEDI-528) have been developed to inhibit IL-9-driven inflammatory responses. Preclinical studies show that anti-IL-9 antibodies reduce airway hyperresponsiveness in asthma models and ameliorate colitis in autoimmune settings. However, clinical trials in asthma yielded mixed results, suggesting context-dependent roles of IL-9. Current research explores bispecific antibodies or combination therapies to enhance efficacy. Challenges include optimizing target engagement and understanding IL-9's dual pro- and anti-tumor effects. These antibodies represent a promising yet evolving approach for immune-mediated diseases.

(Word count: 199)